GOLGA6D

Across TCGA pan-cancer cohorts, GOLGA6D Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GOLGA6D data layer compared with 17 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher GOLGA6D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6D expression acts as an unfavorable survival marker.

BLCA, THYM, and LUAD are the cancer types where GOLGA6D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.710	<.001	48	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GOLGA6D–BLCA (OS)

Open the BLCA breakdown →